1、周文盛等 EGFR基因20外显子插入突变在非小细胞肺癌的研究及其进展 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049789/ 2、Guangjian Yang et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular...
[4] Wang M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre,...
[1]Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220-9.[2]Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics...
[8]Vasconcelos PENS,Kobayashi IS,Kobayashi SS,Costa DB.Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations.JTO Clin Res Rep.2021;2(3):100105.doi:10.1016/j.jtocrr.2020.100105. [9]NCCN Guidelines V...
[2]Riely GJ, Neal JW, Camidge DR, et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 Feb 25. doi: 10.1158/2159-8290.CD-20-1598. ...
3.First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review - PMC (nih.gov)
近年来，随着新药的不断问世，Exon20ins突变逐渐由籍籍无名到长风破浪。期待未来有更多靶向药物获批，EGFR Exon20ins早日迎来精准治疗时代。参考来源 Bai, Q., Wang, J., Zhou, X., EGFR exon20 insertion mutations in non–small cell lung cancer: Clinical implications and recent advances in targeted ...
近日,武田(Takeda)在公布2023年Q1(2023.4-2023.6)业绩的同时,宣布其口服EGFR Exon20ins(20号外显子插入突变)抑制剂Exkivity (莫博赛替尼,Mobocertinib) 一线治疗EGFR Exon20ins突变的非小细胞肺癌(NSCLC)的III期EXCLAIM-2试验因无效而终止。 来源:武田2023一季报 ...
[5]中国临床肿瘤学会非小细胞肺癌专家委员会. EGFR 20 外显子插入突变非小细胞肺癌规范化诊疗中国专家共识(2024 版). 中国肺癌杂志, 2024, 27(7): 485-494. [6] Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular he...
由于缺乏有效的靶向治疗,EGFR exon 20ins肺癌患者的预后相较于其他EGFR突变亚型要差很多。一项筛选了62464例晚期NSCLC患者统计研究数据显示:EGFR exon 20ins患者的中位无进展生存期(PFS)仅有2.86个月,中位总生存期(OS)仅有7.45个月,与其它EGFR突变亚型的10.45个月和25.49个月相比,甚至不到三分之一。 不过,这种...